Engineered immune cells take on tough blood cancers
Disease control
Ongoing
This early-stage trial tests a new treatment called MB-CART19.1 for people whose B-cell blood cancers (like leukemia or lymphoma) have returned or stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to better recognize and attack canc…
Phase: PHASE1 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated May 15, 2026 11:57 UTC